-
Sex-specific differences in alive hospital discharge following infrarenal abdominal aortic aneurysm repair Eur. Heart J. (IF 37.6) Pub Date : 2024-09-24 Anna Louise Pouncey, Michael J Sweeting, Colin Bicknell, Janet T Powell, Jenny Lübcke, Kim Gunnarsson, Anders Wanhainen, Kevin Mani
Background and Aims A longer time to alive hospital discharge following infrarenal abdominal aortic aneurysm (AAA) repair is associated with reduced patient-satisfaction and increased length of stay, hospital-acquired deconditioning, infection and costs. This study investigated sex-specific differences in, and drivers of, the rate of alive hospital discharge. Methods Examination of UK National Vascular
-
Correction to: Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-20
-
Weekly Journal Scan: tirzepatide SURMOUNTs obesity-related obstructive sleep apnoea. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-20 Giovanna Liuzzo,Carlo Patrono
-
Renal artery projectile embolus after cardiac gunshot injury: interventional retrieval. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-20 Anna-Maria Odenthal,Julian A Luetkens,Patrick A Kupczyk
-
Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study Eur. Heart J. (IF 37.6) Pub Date : 2024-09-20 Mathieu Echivard, Jean-Marc Sellal, Chloé Ziliox, Eloi Marijon, Pierre Bordachar, Sylvain Ploux, Karim Benali, Christelle Marquié, Clémence Docq, Didier Klug, Romain Eschalier, Baptiste Maille, Jean-Claude Deharo, Dominique Babuty, Thibaud Genet, Estelle Gandjbakhch, Antoine Da Costa, Olivier Piot, Damien Minois, Jean-Baptiste Gourraud, Pierre Mondoly, Philippe Maury, Serge Boveda, Jean-Luc Pasquié
Background and Aims Prophylactic implantable cardioverter–defibrillators (ICDs) are not recommended until left ventricular ejection fraction (LVEF) has been reassessed 40 to 90 days after an acute myocardial infarction. In the current therapeutic era, the prognosis of sustained ventricular arrhythmias (VAs) occurring during this early post-infarction phase (i.e. within 3 months of hospital discharge)
-
The quest for the holy grail in antithrombotic therapy: revitalized hope for platelet GPVI as a safe and effective antithrombotic target. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-20 James D McFadyen,Xiaowei Wang,Karlheinz Peter
-
Successful management of cardiac hydatidosis complicated by rupture and embolism. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-18 Daniel Barnés-Navarro,Gerard Martí-Aguasca,Aitor Uribarri
-
Traditional Chinese medicine: cardiovascular drug development through a holistic framework. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-17 Milton Packer
-
Correction to: Electrical storm treatment by percutaneous stellate ganglion block: the STAR study. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-17
-
Diet and risk of atrial fibrillation: a systematic review Eur. Heart J. (IF 37.6) Pub Date : 2024-09-17 Monika Gawałko, Melissa E Middeldorp, Arnela Saljic, John Penders, Thomas Jespersen, Christine M Albert, Gregory M Marcus, Christopher X Wong, Prashanthan Sanders, Dominik Linz
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia. Comprehensive modification of established AF risk factors combined with dietary interventions and breaking deleterious habits has been shown to reduce AF burden and recurrence. Numerous AF risk factors, such as diabetes, obesity or hypertension can be partially related to dietary and lifestyle choices. Therefore, dietary interventions
-
Clinical features and outcomes in carriers of pathogenic desmoplakin variants Eur. Heart J. (IF 37.6) Pub Date : 2024-09-17 Alessio Gasperetti, Richard T Carrick, Alexandros Protonotarios, Brittney Murray, Mikael Laredo, Iris van der Schaaf, Ronald H Lekanne, Petros Syrris, Douglas Cannie, Crystal Tichnell, Chiara Cappelletto, Marta Gigli, Kristen Medo, Ardan M Saguner, Firat Duru, Nisha A Gilotra, Stefan Zimmerman, Robyn Hylind, Dominic J Abrams, Neal K Lakdawala, Julia Cadrin-Tourigny, Mattia Targetti, Iacopo Olivotto
Background and Aims Pathogenic variants in the desmoplakin (DSP) gene are associated with the development of a distinct arrhythmogenic cardiomyopathy phenotype not fully captured by either dilated cardiomyopathy (DCM), non-dilated left ventricular cardiomyopathy (NDLVC), or arrhythmogenic right ventricular cardiomyopathy (ARVC). Prior studies have described baseline DSP cardiomyopathy genetic, inflammatory
-
The fascinating story of lipid-lowering drugs, sodium-glucose co-transporter 2 inhibitors and GLP1-R agonists: new light shed on their beneficial effects. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-14 Filippo Crea
-
Clinical trials in-a-dish for cardiovascular medicine Eur. Heart J. (IF 37.6) Pub Date : 2024-09-14 Xuekun Wu, Kyle Swanson, Zehra Yildirim, Wenqiang Liu, Ronglih Liao, Joseph C Wu
Cardiovascular diseases persist as a global health challenge that requires methodological innovation for effective drug development. Conventional pipelines relying on animal models suffer from high failure rates due to significant interspecies variation between humans and animal models. In response, the recently enacted Food and Drug Administration Modernization Act 2.0 encourages alternative approaches
-
Asymptomatic female heterozygous Fabry disease diagnosed through medical check-up. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-13 Hiroto Kawamura,Kazuto Nakamura,Akira Sato
-
Clearing up misunderstandings: addressing issues in recent cardiovascular risk review. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-13 Mina Bakhit,Paul Glasziou,Magnolia Cardona
-
Difficulties in running clinical trials on physical activity. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-13 Emmanuel A Zavalis,Pontus Andell
-
Cardiovascular disease risk communication alone is not enough: why a recent review may be misleading. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-13 Sophie Griffiths,Brian McMillan,Y Kiera Bartlett,David French
-
Re-evaluating concurrent training strategies for cardiovascular risk reduction in overweight or obese adults. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-13 Jiawei Du,Jinghua Hou
-
Red blood cells: a new target to prevent cardiovascular disease? Eur. Heart J. (IF 37.6) Pub Date : 2024-09-11 John Pernow,Jiangning Yang
-
The multifaceted impact of warfare on cardiovascular health. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-11 Rasha Kaddoura,Mohammed Al-Hijji
-
Tackling difficult clinical scenarios on cardiovascular disease in the peripartum period: meeting reports from Pregnancy and the Heart Symposia in Cape Town and Mauritius. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-10 Blanche Cupido,Sanjay Bucktowar,Karen Sliwa
-
What is the role of sex and gender in the future of precision cardiology? Eur. Heart J. (IF 37.6) Pub Date : 2024-09-10 Stefano Ministrini,Teresa Padró
-
Cardio-oncology 2023: insights from the National Societies of Cardiology Journals of the European Society of Cardiology. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-10 Jean-Jacques Monsuez,Plamen Gatzov,Fernando Alfonso,
-
Promoting a healthier Ramadan: addressing mind, body, soul, and heart wellbeing. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-10 Mohammed Y Khanji,Waheeb Al-Azzani,Shams Abdalla,Salman Waqar
-
Integration of a hypertension treatment programme into Nigeria's primary healthcare system: report from a stakeholders and policymakers' workshop. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-10 Chisom Obiezu-Umeh,Mark D Huffman,Dike B Ojji
-
Heart failure with preserved ejection fraction: underdiagnosed and undertreated in patients with tricuspid regurgitation. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-09 Khawaja M Talha,Marco Metra,Javed Butler
-
Management of aortic disease in children with FBN1-related Marfan syndrome Eur. Heart J. (IF 37.6) Pub Date : 2024-09-09 Laura Muiño-Mosquera, Elena Cervi, Katya De Groote, Wendy Dewals, Zina Fejzic, Kalliopi Kazamia, Sujeev Mathur, Olivier Milleron, Thomas S Mir, Dorte G Nielsen, Michal Odermarsky, Anna Sabate-Rotes, Annelies van der Hulst, Irene Valenzuela, Guillaume Jondeau
Marfan syndrome (MFS) is a hereditary connective tissue disorder with an estimated prevalence of 1:5000–1:10 000 individuals. It is a pleiotropic disease characterized by specific ocular, cardiovascular, and skeletal features. The most common cardiovascular complication is aortic root dilatation which untreated can lead to life-threatening aortic root dissection, mainly occurring in adult patients
-
A focus on two rapidly expanding fields: cardio-oncology and genetics. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-07 Filippo Crea
-
Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-07 Nilesh J Samani,Emma Beeston,Chris Greengrass,Fernando Riveros-McKay,Radoslaw Debiec,Daniel Lawday,Qingning Wang,Charley A Budgeon,Peter S Braund,Richard Bramley,Shireen Kharodia,Michelle Newton,Andrea Marshall,Andre Krzeminski,Azhar Zafar,Anuj Chahal,Amadeeep Heer,Kamlesh Khunti,Nitin Joshi,Mayur Lakhani,Azhar Farooqi,Vincent Plagnol,Peter Donnelly,Michael E Weale,Christopher P Nelson
BACKGROUND AND AIMS A cardiovascular disease polygenic risk score (CVD-PRS) can stratify individuals into different categories of cardiovascular risk, but whether the addition of a CVD-PRS to clinical risk scores improves the identification of individuals at increased risk in a real-world clinical setting is unknown. METHODS The Genetics and the Vascular Health Check Study (GENVASC) was embedded within
-
Micro-nanoplastics and cardiovascular diseases: evidence and perspectives. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-06 Francesco Prattichizzo,Antonio Ceriello,Valeria Pellegrini,Rosalba La Grotta,Laura Graciotti,Fabiola Olivieri,Pasquale Paolisso,Bruno D'Agostino,Pasquale Iovino,Maria Luisa Balestrieri,Sanjay Rajagopalan,Philip J Landrigan,Raffaele Marfella,Giuseppe Paolisso
Emerging evidence indicates that chemical exposures in the environment are overlooked drivers of cardiovascular diseases (CVD). Recent evidence suggests that micro- and nanoplastic (MNP) particles derived largely from the chemical or mechanical degradation of plastics might represent a novel CVD risk factor. Experimental data in preclinical models suggest that MNPs can foster oxidative stress, platelet
-
Transfemoral or surgical aortic valve replacement in young low-risk patients with tricuspid and bicuspid aortic valve stenosis. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-05 Niklas Schofer,Stefan Blankenberg
-
Sinus sequestration due to transcatheter heart valve endothelialization after transcatheter aortic valve replacement. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-04 Masatoshi Sato,Nobuhiro Yoshijima,Fumiaki Yashima
-
Pre-existing maternal cardiovascular disease and the risk of offspring cardiovascular disease from infancy to early adulthood Eur. Heart J. (IF 37.6) Pub Date : 2024-09-04 Muhammad Zakir Hossin, Kalliopi Kazamia, Jonas Faxén, André Rudolph, Kari Johansson, Anna Sandström, Neda Razaz
Background and Aims A variety of maternal heart conditions are associated with abnormal placentation and reduced foetal growth. However, their impact on offspring’s long-term cardiovascular health is poorly studied. This study aims to investigate the association between intrauterine exposure to pre-existing maternal cardiovascular disease (CVD) and offspring CVD occurring from infancy to early adulthood
-
Vulnerable plaque and major adverse cardiovascular events: anatomy of a failure. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-04 C Noel Bairey Merz
-
Weekly Journal Scan: SELECT renoprotective effects of semaglutide in non-diabetic, obese patients with cardiovascular disease. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-04 Rocco Vergallo,Massimo Volpe
-
Late gadolinium enhancement and anomalous coronary aortic origin in a large paediatric cohort. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-04 Shagun Sachdeva,Lauren Ferrino,Tam T Doan,Dana Reaves-O'Neal,Stephen Dolgner,Alberto Cipriani,Cristina Basso,Massimo A Padalino,Domenico Corrado,Prakash Masand,Silvana Molossi
-
Weekly Journal Scan: A large Chinese SPRINT supports 'the lower, the better' blood pressure in hypertensive patients at high cardiovascular risk. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-04 Rocco Vergallo,Massimo Volpe
-
From a club of friends to an institution: past successes and future challenges for the European Society of Cardiology. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-02 Thomas F Lüscher
-
Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-02 C Michael Gibson,Danielle Duffy,M Cecilia Bahit,Gerald Chi,Harvey White,Serge Korjian,John H Alexander,A Michael Lincoff,Mark Heise,Bronwyn A Kingwell,Jose C Nicolau,Renato D Lopes,Jan H Cornel,Basil S Lewis,Dragos Vinereanu,Shaun G Goodman,Christoph Bode,Ph Gabriel Steg,Peter Libby,Frank M Sacks,Kevin R Bainey,Paul M Ridker,Kenneth W Mahaffey,Philip Aylward,Stephen J Nicholls,Stuart J Pocock,Roxana
BACKGROUND AND AIMS In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary endpoint through 90 days versus placebo after acute myocardial infarction (MI). Nevertheless, given the well-established relationship between higher low-density lipoprotein cholesterol (LDL-C)
-
Routine Extracorporeal Life Support in Infarct-Related Cardiogenic Shock: 1-Year Results of the ECLS-SHOCK Trial Eur. Heart J. (IF 37.6) Pub Date : 2024-09-02 Steffen Desch, Uwe Zeymer, Ibrahim Akin, Michael Behnes, Daniel Duerschmied, Tienush Rassaf, Amir Abbas Mahabadi, Ralf Lehmann, Ingo Eitel, Tobias Graf, Tim Seidler, Andreas Schuster, Tharusan Thevathasan, Carsten Skurk, Peter Clemmensen, Marcus Hennersdorf, Stephan Fichtlscherer, Ingo Voigt, Melchior Seyfarth, Stefan John, Sebastian Ewen, Axel Linke, Eike Tigges, Peter Nordbeck, Leonhard Bruch, Christian
Extracorporeal life support (ECLS) has been increasingly used in the treatment of severe infarct-related cardiogenic shock in the last decade. The randomised ECLS-SHOCK trial demonstrated no benefit of early routine use on 30-day all-cause death. We herein present mid-term results. At 1-year follow-up, there were no significant differences in all-cause or cardiovascular mortality, neurologic outcome
-
Endometriosis and Long-Term Cardiovascular Risk: A Nationwide Danish study Eur. Heart J. (IF 37.6) Pub Date : 2024-09-02 Eva Havers-Borgersen, Dorthe Hartwell, Charlotte Ekelund, Jawad H Butt, Lauge Østergaard, Christine Holgersson, Morten Schou, Lars Køber, Emil L Fosbøl
Background and aims Endometriosis, a systemic gynecological disease affecting 10% of women in reproductive age, shares pathophysiological characteristics with cardiovascular disease. However, data on the relationship between endometriosis and cardiovascular outcomes are scarce, prompting this study to address the knowledge-gap. Methods Using Danish nationwide registries, women diagnosed with endometriosis
-
Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials Eur. Heart J. (IF 37.6) Pub Date : 2024-09-02 Renate B Schnabel, Juan Benezet-Mazuecos, Nina Becher, William F McIntyre, Alexander Fierenz, Shun Fu Lee, Andreas Goette, Dan Atar, Emanuele Bertaglia, Alexander P Benz, Gregory Chlouverakis, David H Birnie, Wolfgang Dichtl, Carina Blomstrom-Lundqvist, A John Camm, Julia W Erath, Emmanuel Simantirakis, Valentina Kutyifa, Gregory Y H Lip, Philippe Mabo, Eloi Marijon, Lena Rivard, Ulrich Schotten, Marco
Background and aims The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation. Methods These pre-specified analyses of the NOAH-AFNET 6 (n=2534 patients) and ARTESiA (n=4012 patients) trials compared anticoagulation to no anticoagulation in patients with DDAF with or without
-
Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry Eur. Heart J. (IF 37.6) Pub Date : 2024-09-02 Peter van der Meer, Bart van Essen, Charle Viljoen, Michael Böhm, Alice Jackson, Denise Hilfiker-Kleiner, Julian Hoevelmann, Alexandre Mebazaa, Hasan Ali Farhan, Sorel Goland, Wouter Ouwerkerk, Mark C Petrie, Petar M Seferović, Jasper Tromp, Karen Sliwa, Johann Bauersachs
Background and Aims Peripartum cardiomyopathy (PPCM) remains a serious threat to maternal health around the world. While bromocriptine, in addition to standard treatment for heart failure, presents a promising pathophysiology-based disease-specific treatment option in PPCM, the evidence regarding its efficacy remains limited. This study aimed to determine whether bromocriptine treatment is associated
-
Bailout glycoprotein IIb/IIIa inhibitors for coronary microvascular obstruction: guideline-indicated, but does harm outweigh benefit? Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Jasmine Latter,Peter McCartney,Colin Berry
-
Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Thomas H Marwick,Elizabeth Dewar,Mark Nolan,Mitra Shirazi,Peter Dias,Leah Wright,Ben Fitzgerald,Leighton Kearney,Piyush Srivastava,John Atherton,Kazuaki Negishi,Aaron L Sverdlov,Sudhir Wahi,James Otton,Joseph Selvanayagam,Liza Thomas,Paaladinesh Thavendiranathan,
BACKGROUND AND AIMS The detection of cancer therapy-related cardiac dysfunction (CTRCD) by reduction of left ventricular ejection fraction (LVEF) during chemotherapy usually triggers the initiation of cardioprotective therapy. This study addressed whether the same approach should be applied to patients with worsening of global longitudinal strain (GLS) without attaining thresholds of LVEF. METHODS
-
From Setbacks to Success: Building a Promising Path for Strain-Guided Cardioprotection during Anthracycline Treatment. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Ana Barac,Lauren Mauro,Kathleen Harnden
-
Quantifying antihypertensive effects of GLP-1 agonists. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Jordana B Cohen,Adam P Bress
-
CHA2DS2-VASc or a non-sex score (CHA2DS2-VA) for stroke risk prediction in atrial fibrillation: contemporary insights and clinical implications. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Gregory Y H Lip,Konsta Teppo,Peter Brønnum Nielsen
-
Non-HDL-cholesterol reduction: the challenges of applying clinical trial results in the real world. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Bart De Geest,Sophie Van Linthout
-
Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 ,,,,
BACKGROUND AND AIMS To improve upon the estimation of 10-year cardiovascular disease (CVD) event risk for individuals without prior CVD or diabetes mellitus in the Asia-Pacific region by systematic recalibration of the SCORE2 risk algorithm. METHODS The sex-specific and competing risk-adjusted SCORE2 algorithms were systematically recalibrated to reflect CVD incidence observed in four Asia-Pacific
-
Infective endocarditis in congenital heart disease: the expected and the unexpected. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Stefano Caselli,Christine Attenhofer Jost,Matthias Greutmann
-
The SEX-SHOCK score - The Emperor's New Clothes? Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Karl-Patrik Kresoja,Maria Rubini Giménez,Holger Thiele
-
Invited editorial on "Outcome of aortic valve replacement versus conservative treatment in asymptomatic patients with severe aortic stenosis - Five years follow-up of the AVATAR randomized controlled trial" by Banovic et al. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Andreas Martinsson,Anders Jeppsson
-
Acoustic-based rule out of stable coronary artery disease: the FILTER-SCAD trial. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Louise Hougesen Bjerking,Kim Wadt Skak-Hansen,Merete Heitmann,Jens Dahlgaard Hove,Sune Ammentorp Haahr-Pedersen,Henrik Engblom,David Erlinge,Sune Bernd Emil Werner Räder,Jens Brønnum-Schou,Tor Biering-Sørensen,Camilla Lyngby Kjærgaard,Søren Strange,Søren Galatius,Eva Irene Bossano Prescott
BACKGROUND AND AIMS Overtesting of low-risk patients with suspect chronic coronary syndrome (CCS) is widespread. The acoustic-based coronary artery disease (CAD) score has superior rule-out capabilities when added to pre-test probability (PTP). FILTER-SCAD tested whether providing a CAD score and PTP to cardiologists was superior to PTP alone in limiting testing. METHODS At six Danish and Swedish outpatient
-
Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Marko Banovic,Svetozar Putnik,Bruno R Da Costa,Martin Penicka,Marek A Deja,Martin Kotrc,Radka Kockova,Sigita Glaveckaite,Hrvoje Gasparovic,Nikola Pavlovic,Lazar Velicki,Stefano Salizzoni,Wojtek Wojakowski,Guy Van Camp,Sinisa Gradinac,Michael Laufer,Sara Tomovic,Ivan Busic,Milica Bojanic,Arsen Ristic,Andrea Klasnja,Milos Matkovic,Nikola Boskovic,Katarina Zivic,Miodrag Jovanovic,Serge D Nikolic,Bernard
BACKGROUND AND AIMS The question of when and how to treat truly asymptomatic patients with severe aortic stenosis (AS) and normal left ventricular (LV) systolic function is still subject to debate and ongoing research. Here, the results of extended follow-up of the AVATAR trial are reported (NCT02436655, clinical trials.gov). METHODS The AVATAR trial randomly assigned patients with severe, asymptomatic
-
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Caroline J Coats,Ahmad Masri,Roberto Barriales-Villa,Theodore P Abraham,D Marshall Brinkley,Brian L Claggett,Albert Hagege,Sheila M Hegde,Carolyn Y Ho,Ian J Kulac,Matthew M Y Lee,Martin S Maron,Iacopo Olivotto,Anjali T Owens,Scott D Solomon,Jacob Tfelt-Hansen,Hugh C Watkins,Daniel L Jacoby,Stephen B Heitner,Stuart Kupfer,Fady I Malik,Lisa Meng,Amy Wohltman,James L Januzzi,
BACKGROUND AND AIMS The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy (oHCM) is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations between clinical characteristics and baseline concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI), and
-
Natriuretic Peptides and Cardiac hs-Troponins as Surrogates of Cardiomyocyte Stress - Clinical Value in HCM? Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Evangelos Giannitsis,Norbert Frey,Hugo A Katus
-
Never too soon to start cardiovascular prevention: the earlier the better. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Filippo Crea
-
Periprocedural myocardial infarction: thresholds of (in)significance. Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Yousif Ahmad,Alexandra J Lansky
-
Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy Eur. Heart J. (IF 37.6) Pub Date : 2024-09-01 Pablo Garcia-Pavia, Artur Oręziak, Ahmad Masri, Roberto Barriales-Villa, Theodore P Abraham, Anjali T Owens, Morten K Jensen, Wojciech Wojakowski, Tim Seidler, Albert Hagege, Neal K Lakdawala, Andrew Wang, Matthew T Wheeler, Lubna Choudhury, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Sheila M Hegde, Iacopo Olivotto
Background and Aims Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long–term effects of mavacamten. Methods Participants from EXPLORER-HCM (NCT03470545) could enrol in MAVA-LTE upon study completion. Results At the latest data cut-off